Daporinad

Daporinad
Clinical data
Drug class	NAMPT inhibitor
Identifiers
	IUPAC name (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide;
CAS Number	658084-64-1;
PubChem CID	6914657;
IUPHAR/BPS	7745;
DrugBank	DB12731;
ChemSpider	5290535;
UNII	V71TF6V9M7;
ChEBI	CHEBI:187413;
ChEMBL	ChEMBL566757;
CompTox Dashboard (EPA)	DTXSID101026050 ;
ECHA InfoCard	100.316.982
Chemical and physical data
Formula	C24H29N3O2
Molar mass	391.515 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3;
	InChI InChI=1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)/b12-11+; Key:KPBNHDGDUADAGP-VAWYXSNFSA-N;

Daporinad (FK866, APO866), is a drug which acts as a selective inhibitor of the enzyme nicotinamide phosphoribosyltransferase (NAMPT). Levels of this enzyme are elevated in certain forms of cancer such as leukemia, and it was hoped that NAMPT inhibitors would be useful in the treatment of cancer. Unfortunately, dapinorad was unsuccessful in clinical trials due to lack of efficacy, but it still has antiinflammatory effects and may be useful for other medical applications such as arthritis, as well as being widely used as a tool compound for the study of NAMPT and its function.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Daporinad was originally identified and developed by Klinge Pharma G.m.b.H.,^[8] Development rights then moved through a corporate chain in which Fujisawa Deutschland GmbH^[9] which later merged into Astellas held APO866/FK866 and subsequently out-licensed the worldwide development and marketing rights to the Danish oncology company TopoTarget in 2005, after which TopoTarget merged with BioAlliance Pharma to form Onxeo, which later rebranded as Valerio Therapeutics.^[10]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Related Articles